Abstract
Background As the coronavirus cases continue to surge, the urgent need for universal testing to identify positive cases for effective containment of this highly contagious pandemic has become the center of attention worldwide. However, in spite of extensive discussions, very few places have even attempted to implement it. We evaluated the efficacy of widespread testing in creating a safe workplace in our healthcare community including staff and patients.
Furthermore, we assessed the rate of new infections in patients undergoing electrophysiology (EP) procedure, to see if identification and exclusion of positive cases facilitated establishment of a risk-free operating environment.
Methods Universal testing was conducted in subjects with no symptoms of COVID-19 including patients and their caregivers and staff in our electrophysiology units along with the Emergency Medical Service (EMS) staff (n=1670)
Results Of 1670, 758 (45.4%) were EP patients, and the remaining 912 were caregivers, EMS staff and hospital staff from EP clinic and lab. Viral-RNA test revealed 64 (3.8%) positives in the population. A significant increase in the rate of positives was observed from April to June, 2020 (p=0.02). Procedures of positive cases (n=31) were postponed until they tested negative at retesting on day 14. Staff testing positive (n=33) were retested before going back to work after 2 weeks. Because of suspected exposure, 67 staff were retested and source was traced. No new infections were reported in patients during the hospital stay or within 2-weeks after the procedure.
Conclusion Universal testing to identify positive cases was helpful in creating and maintaining a safe working environment without exposing patients and staff to new infections in the EP unit at the hospital.
Trial Registration Number clinicaltrials.gov: NCT04352764
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04352764
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
St. David's HealthCare Institutional Review Board, 919 East 32nd Street Austin, Texas 78705
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclosures: Dr. Natale is a consultant for Boston Scientific, Biosense Webster, St. Jude/Abbott Medical, Biotronik, Baylis and Medtronic
Data Availability
Deidentified data will be available only with the permission of the corresponding author and for research purpose only